Moderna (MRNA) Q1 FY26 earnings call

Moderna delivered a strong Q1 FY26, exceeding revenue guidance with $0.4 billion, primarily from international partnerships, and reiterated its full-year revenue growth target. The company maintained financial discipline, reducing adjusted cash costs, while advancing its pipeline with new product approvals in the EU and expanded oncology trials. Despite a GAAP net loss driven by a litigation settlement, Moderna ended the quarter with a robust cash position, signaling continued investment in its diverse portfolio.